Jin Jiajia, Zhan Ping, Katoh Masaru, Kobayashi Susumu S, Phan Kevin, Qian Hong, Li Huijuan, Wang Xiaoxia, Wang Xihua, Song Yong
Department of Respiratory Medicine, Nanjing General Hospital of Nanjing Military Command, Southeast University, Nanjing 210009, China.
Department of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing 210002, China.
Transl Lung Cancer Res. 2017 Feb;6(1):97-108. doi: 10.21037/tlcr.2017.02.07.
β-catenin is a key component of the canonical Wnt pathway, which plays pivotal roles in malignant transformation and cancer progression. Several studies have reported the clinical significance of the expression level of β-catenin in different subcellular locations. This meta-analysis aimed to assess the prognostic value of β-catenin expression patterns in patients with non-small cell lung cancer (NSCLC).
PubMed and Embase databases were searched to identify all articles referring to the association between β-catenin expression level and outcomes of patients of NSCLC up to November 2016. We included eligible studies to summarize the extracted data in terms of pooled hazard ratios (HRs) and their 95% confidence intervals (95% CIs).
A total of 24 studies published between 2000 and 2016 were eligible for this meta-analysis. The total number of patients with NSCLC included was 2,807. Pooled HRs and 95% CIs suggested that positive β-catenin expression in membrane was associated with higher survival rates (HR: 0.53; 95% CI: 0.32-0.87), whereas β-catenin expression in cytoplasm and nucleus had unfavorable impacts on survival rates with HR of 1.63 (95% CI: 1.34-1.99) and HR of 3.15 (95% CI: 1.97-5.05), respectively. But, there was no significant association between β-catenin expression in abnormal pattern with prognosis (HR: 1.38; 95% CI: 0.61-3.15). Publication bias was absent in all of the four outcomes. Sensitivity analysis revealed that the results of this meta-analysis were robust.
Reduced membranous β-catenin, positive expression of cytoplasmic or nuclear β-catenin is all correlated with poor prognosis, although we did not identify a significant association between abnormal β-catenin expression and clinical outcome of NSCLC patients. The meta-analysis suggested that membranous, cytoplasmic and nuclear β-catenin all could serve as an important prognosticator for patients with NSCLC.
β-连环蛋白是经典Wnt信号通路的关键组成部分，在恶性转化和癌症进展中起关键作用。多项研究报道了β-连环蛋白在不同亚细胞定位的表达水平的临床意义。本荟萃分析旨在评估β-连环蛋白表达模式在非小细胞肺癌（NSCLC）患者中的预后价值。
检索PubMed和Embase数据库，以识别截至2016年11月所有提及β-连环蛋白表达水平与NSCLC患者预后之间关联的文章。我们纳入符合条件的研究，以汇总提取的数据，包括合并风险比（HRs）及其95%置信区间（95% CIs）。
共有2000年至2016年间发表的24项研究符合本荟萃分析的条件。纳入的NSCLC患者总数为2807例。合并HRs和95% CIs表明，膜上β-连环蛋白阳性表达与较高的生存率相关（HR：0.53；95% CI：0.32 - 0.87），而细胞质和细胞核中β-连环蛋白表达对生存率有不利影响，HR分别为1.63（95% CI：1.34 - 1.99）和3.15（95% CI：1.97 - 5.05）。但是，β-连环蛋白异常模式表达与预后之间无显著关联（HR：1.38；95% CI：0.61 - 3.15）。所有四个结果均不存在发表偏倚。敏感性分析表明本荟萃分析的结果可靠。
膜β-连环蛋白减少、细胞质或细胞核β-连环蛋白阳性表达均与预后不良相关，尽管我们未发现β-连环蛋白异常表达与NSCLC患者临床结局之间存在显著关联。该荟萃分析表明，膜、细胞质和细胞核β-连环蛋白均可作为NSCLC患者的重要预后指标。
